Cargando…
Modeling the Cost and Health Impacts of Diagnostic Strategies in Patients with Suspected Transthyretin Cardiac Amyloidosis
BACKGROUND: Transthyretin cardiac amyloidosis (ATTR‐CMP) is an increasingly recognized and treatable cause of heart failure with preserved ejection fraction. Multimodality cardiac imaging is recommended for ATTR‐CMP diagnosis, but its cost‐effectiveness in current clinical practice has not been well...
Autores principales: | Ge, Yin, Pandya, Ankur, Cuddy, Sarah A. M., Singh, Amitoj, Singh, Avinainder, Dorbala, Sharmila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683684/ https://www.ncbi.nlm.nih.gov/pubmed/36102240 http://dx.doi.org/10.1161/JAHA.122.026308 |
Ejemplares similares
-
Mitra-clip in Transthyretin Amyloidosis Cardiomyopathy A Case Series
por: Cuddy, Sarah, et al.
Publicado: (2020) -
Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis
por: Giblin, Gerard T, et al.
Publicado: (2022) -
Transthyretin Cardiac Amyloidosis: Underrecognized in the Underrepresented
por: Leedy, Douglas J., et al.
Publicado: (2023) -
Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
por: Falk, Rodney H., et al.
Publicado: (2021) -
Reply: Dual Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Do We Have Enough Evidence?
por: Singal, Aayush Kumar, et al.
Publicado: (2022)